# A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Study · id `cardio:ct-nct07595549` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07595549](<https://clinicaltrials.gov/study/NCT07595549>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07595549

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 954 participants.

## Technical summary

Registry record NCT07595549. Randomized; double masking; primary purpose treatment. Start 2026-06-10 (actual); primary completion 2028-05-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 954 participants (planned count; ClinicalTrials.gov record NCT07595549, source copy `cardio:ctgov-nct07595549-2026-11-05`, retrieved 2026-11-18)
- Started: 2026-06-10 (actual) (ClinicalTrials.gov record NCT07595549, source copy `cardio:ctgov-nct07595549-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2028-05-04 (anticipated) (ClinicalTrials.gov record NCT07595549, source copy `cardio:ctgov-nct07595549-2026-11-05`, retrieved 2026-11-18)
- Completion: 2028-06-21 (anticipated) (ClinicalTrials.gov record NCT07595549, source copy `cardio:ctgov-nct07595549-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Brazil; Canada; France; Germany; Italy; Japan; Mexico; Poland; South Korea; Spain (ClinicalTrials.gov record NCT07595549, source copy `cardio:ctgov-nct07595549-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07595549-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Condition: Obesity
- Condition: Overweight and/or Obesity
- Condition: Overweight
- Intervention (Drug): PF-08653944
- Intervention (Other): Placebo
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: 75dbbfc48b5941551135acccd91f8e080f79b5fecea52e71831f0ee99d269b87
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
